Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioVie Inc.
  6. Summary
    BIVI   US09074F2074

BIOVIE INC.

(BIVI)
  Report
Delayed Nasdaq  -  04:00:01 2023-03-24 pm EDT
8.160 USD   -0.43%
03/23Biovie Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
03/21BioVie Announces Data from Phase 2 Parkinson's Disease Trial Accepted for Presentation at AD/PD 2023
AQ
03/15BioVie Day says webinar registration now open for investors
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2023 03/21/2023 03/22/2023 03/23/2023 03/24/2023 Date
9.24(c) 10.2(c) 9.04(c) 8.195(c) 8.16 Last
618 151 575 840 409 201 1 098 475 430 349 Volume
-6.57% +10.39% -11.37% -9.35% -0.43% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 - - -
Net income 2023 -57,5 M - -
Net Debt 2023 - - -
P/E ratio 2023 -4,38x
Yield 2023 -
Sales 2024 - - -
Net income 2024 -81,1 M - -
Net Debt 2024 - - -
P/E ratio 2024 -5,44x
Yield 2024 -
Capitalization 285 M 285 M -
Capi. / Sales 2023 -
Capi. / Sales 2024 -
Nbr of Employees 13
Free-Float 20,1%
More Financials
Company
BioVie Inc. is a clinical-stage company. The Company is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening... 
Read more
More about the company
Ratings of BioVie Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about BIOVIE INC.
03/23Biovie Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
03/21BioVie Announces Data from Phase 2 Parkinson's Disease Trial Accepted for Presentation ..
AQ
03/15BioVie Day says webinar registration now open for investors
AQ
03/14BioVie Announces Registration Details for "BioVie Day" Webinar
AQ
03/13Biovie Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)
AQ
03/13BioVie Pauses Patient Enrollment for Phase 2b Trial of BIV201 for Treatment of Refracto..
MT
03/13BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouragi..
AQ
03/13BioVie Inc. Announces the Pausing of Patient Enrollment in Ascites Phase 2B Trial, Enco..
CI
03/09BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference
AQ
03/06BioVie Shares Surge on Preliminary 'Encouraging' Data From Phase 2 Trial of NE3107 to T..
MT
03/06Biovie : Management Change - Form 8-K
PU
03/06Biovie Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
03/06BioVie Inc. Announces Additional Findings from Phase 2 Parkinson's Disease Trial
CI
03/06Biovie Announces Additional Findings : More patients treated with NE3107 experienced morni..
AQ
03/06BioVie Inc. Announces Executive Changes
CI
More news
News in other languages on BIOVIE INC.
03/13BioVie interrompt le recrutement des patients pour l'essai de phase 2b du BIV201 pour l..
03/13BioVie Inc. annonce l'interruption du recrutement des patients dans l'essai de phase 2B..
03/06Les actions de BioVie bondissent suite aux données préliminaires "encourageantes" de l'..
03/06BioVie Inc. annonce des résultats supplémentaires de l'essai de phase 2 sur la maladie ..
03/06BioVie Inc. annonce des changements au sein de sa direction
More news
Analyst Recommendations on BIOVIE INC.
More recommendations
ETFs positioned on BIOVIE INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.01%-3.97%United_States
Vanguard Extended Market ETF - USD0%-2.10%United_States
More ETFs positioned on BIOVIE INC.
Chart BIOVIE INC.
Duration : Period :
BioVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,16 $
Average target price 9,75 $
Spread / Average Target 19,5%
EPS Revisions
Managers and Directors
Cuong Viet Do President, Chief Executive Officer & Director
Joanne Wendy Kim Chief Financial Officer, Secretary & Treasurer
James D. Lang Chairman
Joseph M. Palumbo Chief Medical Officer
Michael Sherman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOVIE INC.5.47%287
REGENERON PHARMACEUTICALS, INC.11.18%85 611
VERTEX PHARMACEUTICALS5.53%78 349
WUXI APPTEC CO., LTD.-1.06%34 400
BIONTECH SE-13.87%31 444
GENMAB A/S-13.29%24 332
Secure and increase the performance of your investments with our team of experts at your side.
Securing my Investments
fermer